GERN Share Price Performance

GERN Community Fair Values

AN
AnalystConsensusTarget
Consensus Narrative from 9 Analysts
EU Approval And US Initiatives Will Expand Future Markets
Key Takeaways European expansion with RYTELO's approval and launch could significantly boost revenue through international growth and increased market reach. Strategic improvements in operations, leadership, and medical engagement aim to capture U.S. market opportunities and increase RYTELO adoption, enhancing revenue growth.
US$3.39
FV
65.5% undervalued intrinsic discount
65.95%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
10 days ago author updated this narrative
WA
WaneInvestmentHouse
Community Contributor
Q1 2025 Earnings Call Highlights: Navigating Revenue Challenges and Strategic amid investor court case
Release Date: May 07, 2025 Q1 RYTELO Net Revenues: $39.4 million, down $8 million from Q4. Cash and Marketable Securities: Approximately $457.5 million as of March 31, 2025.
US$2.42
FV
51.7% undervalued intrinsic discount
98.00%
Revenue growth p.a.
0users have liked this narrative
1users have commented on this narrative
4users have followed this narrative
3 months ago author updated this narrative

View all narratives

Recent GERN News & Updates

No updates

Geron Corporation Key Details

Last Reported Earnings

Mar 31, 2025

Next Reporting Earnings

Aug 06, 2025

Earnings per share (EPS): -0.22
Gross Margin: 8.07%
Net Profit Margin: -119.54%
Debt/Equity Ratio: 44.3%

View full report ›

Geron Corporation Competitors

View more competitors

About GERN

Founded: 1990
Employees: 229
CEO: Dawn Bir
WebsiteView website: www.geron.com

Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. It offers RYTELO a telomerase inhibitor for the treatment f adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia. The company was incorporated in 1990 and is headquartered in Foster City, California.

U.S. Market Performance

7 Days: -2.7%
3 Months: 10.7%
1 Year: 17.5%
Year to Date: 5.9%

In the last week, the market has fallen 2.7%, dragged down most by the Financials. In the last year, the market is actually up 18%. As for the next few years, earnings are expected to grow by 15% per annum. Market details ›

💥 How Agentic AI Could Change Every Industry

Richard Bowman

August 2025

This week, we’re diving deeper into the world of agentic AI. We’re zeroing in on the core technologies that make these intelligent agents actually reliably work. We explore what all this could mean for software, start-ups, and most importantly, the opportunities and risks each industry faces by adopting Agentic AI.

Last Week

Geron Stock Price